Cagrilintide vs Ipamorelin
Extensively Studied vs Well Studied
synergistic Mechanism-based · 51% Cagrilintide helps counteract the insulin-disrupting effects of Ipamorelin. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Cagrilintide Ipamorelin
Weight 4,409.01 Da 711.85 Da
Half-life ~7 days (159-195 hours) ~2 hours
Chain 37 amino acids 5 amino acids
Type Amylin receptor agonist Growth hormone secretagogue
Key Benefits
Cagrilintide
01 FDA development candidate with extensive Phase 3 data
02 Superior weight loss in combination with semaglutide (22.7%)
03 Once-weekly convenience
04 2.2% HbA1c reduction with CagriSema
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Dosing Protocols
Cagrilintide
2.4mg weekly (after escalation) / Once weekly, same day each week
Weight Loss (Monotherapy) 2.4mg Once weekly
Weight Loss (CagriSema) 2.4mg + semaglutide 2.4mg Once weekly
Type 2 Diabetes Management 2.4mg weekly Once weekly
Dose Escalation Protocol 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg Weekly increases over 16 weeks
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Side Effects
Cagrilintide
Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Contraindications
Not recommended in pregnancy or breastfeeding
Not yet commercially available (FDA approval expected Q1 2026)
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Research Evidence
Cagrilintide Ipamorelin
Status Extensively Studied Well Studied
References 3 studies 5 studies
Latest December 2025 October 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.